Skip to content. | Skip to navigation

Personal tools
Log in
Sections
You are here: Home › Faculty › Dr. Marianne Sadar › Publications › Marianne Sadar Publications

Marianne Sadar Publications

by Marianne Sadar — last modified Nov 03, 2011 10:35 AM
Complete Publications List updated January 2010

  1. Sadar MD. Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer. World journal of urology. 2011 Aug 11.

  2. Sadar MD. Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity. Cancer Res. 2011 Feb 15; 71(4):1208-13.

  3. Haile S, Sadar MD. Androgen receptor and its splice variants in prostate cancer. Cellular and molecular life sciences : CMLS. 2011 Jul 12.

  4. Haile S, Lal A, Myung J-K, Sadar MD. FUS/TLS Is a Co-Activator of Androgen Receptor in Prostate Cancer Cells. PLoS ONE. 2011 Jan 1; 6(9):e24197.

  5. Romanuik TL, Marra MA, Sadar MD. Long serial analysis of gene expression of hormonal progression of prostate cancer to androgen independence. BMC Medical Genomics, 2010 Sep 24;3:43.

  6. Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, Watt K, Tam T, Yang YC, Banuelos AC, Williams DE, McEwan IJ, Wang YZ, Sadar MD. Regression of castrate-recurrent prostate cancer by a small molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010 Jun 15; 17(6)535-46.

  7. Lin D, Bayani J, Wang Y, Sadar MD, Yoshimoto M, Gout GW, Squire JA, Wang YZ. Development of metastatic and non-metastatic tumor lines from a patient’s prostate cancer specimen-Identification of a small subpopulation with metastatic potential in the primary tumor. The Prostate 2010 Nov 1;70(15):1636-44

  8. Chiu HHL, Yong TMK, Wang J, Wang Y, Vessella RL, Ueda T, Wang YZ, Sadar MD. Induction of Neuronal Apoptosis Inhibitory Protein Expression in Resonse to Androgen Deprivation in Prostate Cancer. Cancer Letters, 2010 Jun 28;292(2):176-85

  9. Romanuik TL, Wang G, Holt RA, Jones SJ, Marra MA, Sadar MD. Identification of novel androgen-responsive genes by sequencing of LongSAGE libraries. BMC Genomics. 2009 Oct 15;10:476.

  10. Wang G, Haile S, Comuzzi B, Tien AH, Wang J, Yong TMK, Jelescu-Bodos AE, Blaszczyk N., Vessella RL, Masri B, and Sadar MD. Osteoblast-derived factors induce an expression signature that identifies prostate cancer metastasis and hormonal progression. Cancer Research, 2009 Apr 15;69(8):3433-42.

  11. Yee J, Sadar MD, Sin DD, Kuzyk M, Xing L, Rattenbury J, McWilliams A, Man SFP, Lam S. Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection.. J Clinical Oncology, 2009 Jun 10;27(17):2787-92. Epub 2009 May 4.

  12. Wang G, Wang J, and Sadar MD. Crosstalk between the androgen receptor and ß-catenin pathways in androgen independent prostate cancer. Cancer Research, 2008 Dec 1;68(23):9918-27.

  13. Sadar MD, Williams DE, Mawji NR, Patrick BO, Chasanah E, Irianto HE, Van Soest R, Andersen RJ. (2008) Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cells. Org. Letts., 2008 Nov 6;10(21):4947-50. Epub 2008 Oct 4.

  14. Lin D, Watahiki A, Zhang F, Liu L, Ling V, Sadar MD, English J, Fazli L, Gleave M, So A, Gout PW Wang Y-Z. ASAP1, a Gene at 8q24, is Associated with Prostate Cancer Metastasis. Cancer Research. 2008 Jun 1;68(11):4352-9.

  15. Myung J-K and Sadar MD. Proteomic research in prostate cancer in Genome Science and Molecular Medicine. Eds, Thangadurai D., Tang W., and Pullaiah T. Regency Publications. In press.

  16. Sadar MD. Role of cAMP in regulating the androgen receptor in Androgen Action in Prostate Cancer. Eds, Tindall DJ and Mohler JL. Springer Publishers. In press.

  17. Quayle SN, Mawji NR, Wang J, Sadar MD. Androgen receptor decoy molecules block the growth of prostate cancer. Proc. Natl. Acad. Sci. USA. 2007 Jan 16: 104(4)1331-1336.

  18. Quayle SN, Sadar MD 14-3-3 sigma increases the transcriptional activity of the androgen receptor in the absence of androgens. Cancer Lett. 2007;254(1):137-45.

  19. Quayle SN, Hare H, Delaney AD, Hirst M, Hwang D, Schein JE, Jones SJ, Marra MA, Sadar MD. Novel expressed sequences identified in a model of androgen independent prostate cancer. BMC Genomics. 2007;8:32.

  20. Quayle SN, Mawji NR, Wang J, Sadar MD. Androgen receptor decoy molecules block the growth of prostate cancer. Proc Antl Acad Sci USA. 2007;104:4 p1331-1336.

  21. Bainbridge MN, Warren RL, Hirst M, Romanuik T, Zeng T, Go A, Delaney A, Griffith M, Hickenbotham M, Magrini V, Mardis ER, Sadar MD, Siddiqui AS, Marra MA, Jones SJ. Analysis of the prostate cancer cell line LNCaP transcriptome using a sequencing-by-synthesis approach. BMC Genomics. 2006;7:246.

  22. Comuzzi B, Sadar MD. Proteomic analyses to identify novel therapeutic targets for the treatment of advanced prostate cancer. Cellscience Reviews. 2006;3(1):61-81.

  23. Wang G, Jones SJ, Marra MA, Sadar MD. Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells. Oncogene. 2006;25:55 p.7311-7323.

  24. Quayle SN, Sadar MD. A truncated isoform of TMEFF2 encodes a secreted protein in prostate cancer cells. Genomics. 2006;87(5):633-7.

  25. Wang G, Sadar MD. Amino-terminus domain of the androgen receptor as a molecular target to prevent the hormonal progression of prostate cancer. J Cell Biochem. 2006;98(1):36-53.

  26. Sobel RE, Wang Y, Sadar MD. Molecular analysis and characterization of PrEC, commercially available prostate epithelial cells. In Vitro Cell Dev Biol Anim. 2006;42(1-2):33-9.

  27. Wang Y, Xue H, Cutz JC, Bayani J, Mawji NR, Chen WG, Goetz LJ, Hayward SW, Sadar MD, Gilks CB, Gout PW, Squire JA, Cunha GR, Wang YZ. An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest. 2005;85(11):1392-404.

  28. Wang Y, Revelo MP, Sudilovsky D, Cao M, Chen WG, Goetz L, Xue H, Sadar MD, Shappell SB, Cunha GR, Hayward SW. Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate. 2005;64(2):149-59.

  29. Le L, Chi K, Tyldesley S, Flibotte S, Diamond DL, Kuzyk MA, Sadar MD. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem. 2005;51(4):695-707.

  30. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: a compendium of old and new lines--part 1. J Urol. 2005;173(2):342-59.

  31. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: a compendium of old and new lines--part 2. J Urol. 2005;173(2):360-72.

  32. Ueda T, Sadar MD, Suzuki H, Akakura K, Sakamoto S, Shimbo M, Suyama T, Imamoto T, Komiya A, Yukio N, Ichikawa T. Interleukin-4 in patients with prostate cancer. Anticancer Res. 2005;25(6C):4595-8.

  33. Cheung PK, Woolcock B, Adomat H, Sutcliffe M, Bainbridge TC, Jones EC, Webber D, Kinahan T, Sadar MD, Gleave ME, Vielkind J. Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis. Cancer Res. 2004;64(17):5929-33.

  34. Meehan KL, Sadar MD. Quantitative profiling of LNCaP prostate cancer cells using isotope-coded affinity tags and mass spectrometry. Proteomics. 2004;4:116-1134.

  35. Blaszczyk N, Masri B, Mawji NR, Ueda T, McAlinden G, Duncan CP, Bruchovsky N, Schweikert HU, Schnabel D, Jones EC, Sadar MD. Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells. Clin Cancer Res. 10:1860-1869.

  36. Meehan KL, Sadar MD. Androgens and androgen receptor in prostate and ovarian malignancies. Frontiers in Bioscience. 2003;8:780-800.

  37. Sadar MD, Akopian V, Beraldi E. Characterization of a new in vivo hollow fiber model for the study of progression of prostate cancer to androgen independence. Mol Cancer Therap. 2002;1:629-637.

  38. Ueda T, Bruchovsky N, Sadar MD. Activation of the N-terminus of the androgen receptor by interleukin-6 via MAPK and STAT3 signal transduction pathways cells. J Biol Chem. 2002;277:7076-7085.

  39. Ueda T, Mawji NR, Bruchovsky N, Sadar MD. Ligand-independent activation of the androgen receptor and the role of the coactivator SRC-1a in prostate cancer cells. J Biol Chem. 2002;277:38087-38094.

  40. Bruchovsky N, Goldenberg SL, Mawji NR, Sadar MD. Evolving aspects of intermittent androgen blockage for prostate cancer: diagnosis and treatment of early tumor progression and maintenance of remission. In, Andrology in the 21st Century, Proceedings of the VIIth International Congress of Andrology, Robaire B, Chemes H, and Morales CR (eds), 2001;pp. 609-623. Medimond Inc..

  41. Sadar MD, Andersson TB. Regulation of cytochrome P450 in a primary culture of rainbow trout hepatocytes. In Vitro Cell Dev Biol Anim. 2001;37(3):180-4.

  42. Bruchovsky N, Klotz LH, Sadar MD, Cook JM, Hoffart D, Godwin L, Warkentin M, Gleave ME, Goldenberg SL. Intermittent androgen suppression for prostate cancer: Canadian prospective trial and related observations. Mol Urol 2000;4:191-199.

  43. Sadar MD, Gleave ME. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Res. 2000;60(20):5825-31.

  44. Sadar MD. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem. 1999;274(12):7777-83.

  45. Sadar MD, Hussain M, Bruchovsky N. Prostate cancer: molecular biology of early progression to androgen independence. Endocr Relat Cancer 1999;6(4):487-502.

  46. Gleave ME, Sato N, Sadar MD, Beraldi E, Bruchovsky N. Butyrate inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP Tumor Model. J Cell Biohchem. 1998;69:271-281.

  47. Sato N, Sadar MD, Bruchovsky N, Saatcioglu F, Rennie PS, Sato S, Lange PH, Gleave ME. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. J Biol Chem. 1997;272(28):17485-94.

  48. Bruchovsky N, Sadar MD, Akakura K, Goldenberg SL, Matsuoka K, Rennie PS. Characterization of 5alpha-reductase gene expression in stroma and epithelium of human prostate. J Steroid Biochem Mol Biol. 1996;59(5-6):397-404.

  49. Sadar MD, Ash R, Sundqvist J, Olsson PE, Andersson TB. Phenobarbital induction of CYP1A1 gene expression in a primary culture of rainbow trout hepatocytes. J Biol Chem. 1996;271(30):17635-43

  50. Sadar MD, Blomstrand F, Andersson TB. Phenobarbital induction of cytochrome P4501A1 is regulated by cAMP-dependent protein kinase-mediated signaling pathways in rainbow trout hepatocytes. Biochem Biophys Res Commun. 1996;225(2):455-61

  51. Sadar MD, Westlind A, Blomstrand F, Andersson TB. Induction of CYP1A1 by GABA receptor ligands. Biochem Biophys Res Commun. 1996;229(1):231-7

  52. Sadar MD, Ash R, Andersson TB. Picrotoxin is a CYP1A1 inducer in rainbow trout hepatocytes. Biochem Biophys Res Commun. 1995;214(3):1060-6

  53. Rogers IH, MacDonald JS, Sadar MD. Uptake of selected organochlorine contaminants in fishes resident in the Fraser River estuary, Vancouver, British Columbia. Water Poll Res J Canada. 1992;27:733-749

  54. McLean E, Sadar MD, Devlin RH, Souza LM, Donalson EM. Growth promotion in coho salmon (Oncorhynchus kisutch) following parenteral administration of recombinant porcine somatotropin: comparison between two ploidy states. Aquat Living Resour. 1991;4:155-160.

  55.  

Page last modified Nov 03, 2011